LF:aVLFA0721p Farmakologie I - přednáška

aVLFA0721p Farmakologie I - přednáška

Lékařská fakulta
podzim 2024

Rozsah

2/0/0. 30. 2 kr. Ukončení: k.
Vyučováno kontaktně

Vyučující

Garance

doc. MUDr. Regina Demlová, Ph.D.
Farmakologický ústav – Teoretická pracoviště – Lékařská fakulta
Kontaktní osoba: doc. Mgr. MVDr. Leoš Landa, Ph.D.
Dodavatelské pracoviště: Farmakologický ústav – Teoretická pracoviště – Lékařská fakulta

Rozvrh

Út 17. 9. 17:30–19:10 Virtuální místnost, Út 24. 9. 17:30–19:10 Virtuální místnost, Út 1. 10. 17:30–19:10 Virtuální místnost, Út 8. 10. 17:30–19:10 Virtuální místnost, Út 15. 10. 17:30–19:10 Virtuální místnost, Út 22. 10. 17:30–19:10 Virtuální místnost, Út 29. 10. 17:30–19:10 Virtuální místnost, Út 5. 11. 17:30–19:10 Virtuální místnost, Út 12. 11. 17:30–19:10 Virtuální místnost, Út 19. 11. 17:30–19:10 Virtuální místnost, Út 26. 11. 17:30–19:10 Virtuální místnost, Út 3. 12. 17:30–19:10 Virtuální místnost, Út 10. 12. 17:30–19:10 Virtuální místnost, Út 17. 12. 17:30–19:10 Virtuální místnost, Út 7. 1. 17:30–19:10 Virtuální místnost

Předpoklady

aVLPF0622p Pathophysiology II - lecture && aVLPA0622c Patologie II - cv.

Omezení zápisu do předmětu

Předmět je určen pouze studentům mateřských oborů.

Mateřské obory/plány

General Medicine (program LF, M-GM)
Všeobecné lékařství (angl.) (program LF, M-VL)

Cíle předmětu

The aims of the course are:
to explain the basic pharmacodynamic and pharmacokinetic processes and principles
to explain the basic principles of therapy of intoxications
to describe the factors that influence the drug effect

Výstupy z učení

Student after the course:
knows basic pharmacodynamic principles
knowns basic pharmacokinetic principles
knows basic factors that influence the effect of drugs
is able to suggest therapeutic measures in case of drug intoxication

Osnova

aVLFA0721p - Pharmacology I - Lectures

General medicine

Autumn semester 2024
1. PHARMACOLOGY AND ITS SUB-BRANCHES (17. 9. 2024)
Definition of pharmacology and its sub-branches of pharmacology. Drug, medical product – basic pharmacological terminology.Principles of correct drug use – types of pharmacotherapy and rational pharmacotherapy.
2. ROUTES OF DRUG ADMINISTRATION, OVERVIEW OF DRUG DOSAGE FORMS (24. 9. 2024)
Classification and overview of drug dosage forms for ready-made production and individual preparation. Drug dosage forms with controlled release. Classification of routes of administration.
3. DRUG DEVELOPMENT LIFE CYCLE, BASIC PRINCIPLES OF BIOLOGICAL THERAPY (1. 10. 2024)
Drug discovery. Preclinical and clinical drug testing. Marketing authorisation. Basic technologies of biologics production, their classification.
4. PHARMACOKINETICS I (8. 10. 2024)
General principles of drug's fate in the organism. Overview of the basic pharmacokinetic processes and parameters.
5. PHARMACOKINETICS II (15. 10. 2024)
Single, continual and repeated drug administration. Principles of therapeutic drug monitoring. Compartment models. Fundamentals of population pharmacokinetics.
6. PHARMACODYNAMICS (22. 10. 2024)
Mechanisms of drug effects – classification, examples. Receptor theory – types of ligands and receptors. Change in drug effect after repeated administration.
7. FACTORS AFFECTING DRUG'S EFFECTS (29. 10. 2024)
Classification, overview and examples of factors affecting drug effects. Fundamentals of pharmacogenetics.
8. PHARMACOVIGILANCE AND DRUG'S SAFETY (5. 11. 2024)
Adverse effects of drugs - classification and characteristics. Pharmacovigilance in clinical research and practice. Therapeutic index, therapeutic range. Drug anamnesis, polypharmacy and introduction to drug interactions.
9. PHARMACOLOGY OF AUTONOMIC NERVOUS SYSTEM - INTRODUCTION, SYMPATHOTROPIC DRUGS (12. 11. 2024)
Overview of pharmacology of sympathetic and parasympathetic nervous system – neurotransmission, receptors. Basic indications of substances affecting sympathetic NS.
10. PHARMACOLOGY OF AUTONOMIC NERVOUS SYSTEM - CHOLINERGIC DRUGS, SPASMOLYTIC DRUGS, MUSCLE RELAXANTS (19. 11. 2024)
Basic indications of substances affecting parasympathetic NS. Definition and use of spasmolytic and muscle relaxant drugs.
11. GLUCOCORTICOIDS, MINERALOCORTICOIDS, IMMUNOPHARMACS AND TARGETED TREATMENT OF AUTOIMMUNE DISEASES, DRUGS USED FOR TREATMENT OF HYPO/HYPERTHYROIDISM (26. 11. 2024)
Overview of adrenocortical hormones, therapeutic use. Overview of drugs affecting the immune system - classification, therapeutic use, basic pharmacological characteristics. Drugs used in diseases of the thyroid gland.
12. ANALGESICS, PHARMACOTHERAPY OF GOUT (3. 12. 2024)
Classification of analgesic drugs. Basic pharmacological characteristics and examples of opioid analgesics, NSAIDs and analgesics-antipyretics. Therapy of pain, co-analgesics. Therapy of gout.
13. THERAPY OF DISEASES WITH CHRONIC BRONCHIAL OBSTRUCTION, H1-ANTIHISTAMINES (10. 12. 2024)
Effects of histamine and possibilities of its antagonization. Classification of antihistamines, drugs used for the treatment of diseases with chronic bronchial obstruction.
14. PHARMACOTHERAPY OF DIABETES MELLITUS (17. 12. 2024)
Insulins and anti-diabetic drugs – classification and basic pharmacological characteristics.
15. PHARMACOLOGY OF HYPOTHALAMO-PITUITARY HORMONES AND SEX HORMONES (7. 1. 2025)
Analogues and antagonists of hypothalamo-pituitary hormones used in pharmacotherapy. Oestrogens, antioestrogens, gestagens, antigestagens, androgens, antiandrogens basic pharmacological characteristics). Uterotonics and tocolytics.

Literatura

povinná literatura

RITTER, James, R. J. FLOWER, Graeme HENDERSON, Yoon Kong LOKE, David J. MACEWAN, Emma S. J. ROBINSON a James FULLERTON. Rang & Dale's pharmacology / James M. Ritter, Rod Flower, Graeme Henderson, Yoon Kong Loke, David MacEvan, Emma Robinson, James Fullerton. Tenth edition. London: Elsevier, 2024, xvii, 850. ISBN 9780323873963. info
http://search.ebscohost.com/login.aspx?direct=true&db=nlebk&AN=1160493&lang=cs&site=ehost-live
Practicals in Pharmacology, 2009, Náhradní obsah: http://portal.med.muni.cz/article-491-practicals-in-pharmacology.html

doporučená literatura

Pharmaceutical practice. Edited by Judith A. Rees - Ian Smith - Jennie Watson. 5th ed. Edinburgh: Churchill Livingstone Elsevier, 2014, xvii, 552. ISBN 9780702051432. info
WHALEN, Karen. Pharmacology. Edited by Richard Finkel - Thomas A. Panavelil. 6th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2015, xi, 664. ISBN 9781451191776. info

neurčeno

Waller, Derek - Renwick, Andrew G. - Hillier, Keith. Medical pharmacology and therapeutics. 3rd ed. New York : Elsevier Saunders, 2009. ix, 744 p. ISBN 0-7020-2991-2.
Ritter, James M. - Lewis, Lionel D. - Mant, Timothy G.K. - Ferro, Albert. A Textbook of Clinical Pharmacology and Therapeutics, 5th Ed., Hodder Arnold, 2008. 465 s. ISBN 978-0-340-90046-8
Pharmacology. Edited by Michelle Alexia Clark. 5th ed. Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012, xii, 612. ISBN 9781451113143. info

Záložky

https://is.muni.cz/ln/tag/LF:aVLFA0721p!

Výukové metody

Lectures will provide theoretical background. The lectures are followed by practical exercises. The lectures discuss the basic issues of the subject. This knowledge is further deepened via specific practical tasks in exercises. According to the syllabi, materials for self-study and preparation will be available in the study materials for each topic, including references to the relevant chapters in the textbook.

Metody hodnocení

Colloquium - ROPOT test - 40 multiple-choice questions with 3 - 5 answer options. The number of correct answers is given.

Student gets 2 points for each completely correct answer, i.e. maximum 80 points for the whole multiple-choice test. The MCQ test can be repeated only twice.

To pass the colloquium successfully the student has to obtain at least 48 points.

Vyučovací jazyk

Angličtina

Informace učitele

LIST OF QUESTIONS FOR THE FINAL EXAM (at the end of spring semester)

General pharmacology:

1. Pharmacology, sub-branches, origin of drugs, drug names. • 2. Types of pharmacotherapy, rules of rational and safe pharmacotherapy. The question of drug misuse. • 3. Preclinical and clinical trials, stages. • 4. Basic legislation related to drug use, Sources of information on drugs and medicinal products. • 5. Solid and gaseous pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics. • 6. Semi-solid and liquid pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics. • 7. Routes of drug administration – overview, characteristics. • 8. Drug absorption, presystemic elimination, drug bioavailability. • 9. Drug distribution, volume of distribution, redistribution. General principles of drug movement through the body. • 10. Drug elimination, processes of the first and zero order, drug accumulation. • 11. Drug biotransformation – stages, examples. • 12. Drug excretion (ways of excretion, possibilities of their influence). • 13. Therapeutic monitoring of drugs (TDM). • 14. Pharmacokinetics of single, repeated and continual drug administration. • 15. Modes of drug action • 16. Synergism and antagonism in drug effect (pharmacokinetics, pharmacodynamics). • 17. Dose – response curves, types of doses, drug anamnesis, patient‘s adherence. • 18. Adverse drug reactions (types, categories, examples). • 19. Pharmacovigilance, drug safety. • 20. Influence of repeated administration on drug efficacy - examples of tolerance and tachyphylaxis. Primary resistance of the patient to the treatment. • 21. Factors influencing the drug effect – examples. • 22. Pharmacotherapy in elderly, the influence of co-morbidities on drug effect, polypharmacy. • 23. Pharmacotherapy in paediatric population, in breastfeeding women. Drugs influencing breast feeding. • 24. Pharmacotherapy in pregnancy, drug teratogenicity. • 25. Pharmacogenetics, influence of genetic polymorphisms on pharmacokinetics and pharmacodynamics of drugs. • 26. Pharmacokinetic drug interactions (desirable and undesirable) – overview, examples. • 27. Pharmacodynamic drug interactions (desirable and undesirable) – overview, examples. • 28. Principles of biological treatment – classification, technology, examples of clinical use.

Special pharmacology:

1. Sympathomimetics - overview of single classes and their indications, examples of drugs • 2. Sympatholytics - overview of single classes and their indications, examples of drugs • 3. Cholinomimetics • 4. Cholinolytics • 5. Antispasmodics - GIT + UGT • 6. Opioid analgesics • 7. NSAIDs, non-opioid analgesics, antimigraine agents • 8. Antiuratics, antirheumatics incl. DMARDs • 9. General anaesthetics • 10. Local anaesthetics • 11. Muscle relaxants • 12. Antidiabetics (except insulins) • 13. Insulins • 14. Analogues and antagonists of oestrogens, gestagens and androgens – their basic pharmacology; HRT, hormonal contraception • 15. Analogues and antagonists of H-P axis hormones used in pharmacology; uterotonics and tocolytics • 16. Glucocorticoids • 17. Immunostimulants + immunosuppressants (except glucocorticoids) • 18. Drugs used in osteoporosis, pharmacology of thyroid gland • 19. Antiasthmatics, drugs used in COPD • 20. Antitussives, mucoactive drugs • 21. H1 antihistamines • 22. Antipsychotics • 23. Drugs of neurogenerative diseases (Parkinson’s disease; dementia) • 24. Antidepressants - iMAO+SSRI+NDRI • 25. Antidepressants - tricyclic, NASSA, MASSA, SARI, SNRI, NARI, SMS • 26. Nootropics, cognitive enhancers • 27. Psychostimulants. Drugs used in ADHD. Psychotomimetics. • 28. Anticonvulsants • 29. Hypnosedatives, anxiolytics • 30. Principles of antibacterial therapy – overview, modes of action, resistance, MIC, MBC • 31. Penicillins, carbapenems • 32. Cephalosporines, monobactams • 33. Tetracyclines + related ATBs, amphenicoles • 34. Macrolides and related ATBs, lincosamides • 35. Aminoglycosides, glycopeptides, polymyxins • 36. Sulphonamides, nitrofurans and nitroimidazoles • 37. Quinolones, antituberculotics • 38. Antimycotics • 39. Dermatologics – overview of classes, drugs and effects • 40. Antivirotics • 41. Antiemetic drugs, prokinetics, antivertigo drugs • 42. Laxatives, antidiarrhoics, drugs of infectious diarrhoeas • 43. Antiulcer agents, hepatoprotectives and drugs influencing the production and excretion of bile • 44. Drugs for inflammatory bowel disease • 45. Alkylating cytostatics and other drugs aiming on DNA in oncology • 46. Antimetabolites + hormonal therapy in oncology • 47. Targeted treatment in oncology • 48. Biological treatment of autoimmune diseases • 49. Hypolipidaemics, anti-obesity drugs • 50. Nitrates and other vasodilators • 51. Drugs targeting RAAS • 52. Diuretics and aldosterone antagonists • 53. Beta blockers + central antihypertensives • 54. Calcium channel blockers, α1-lytics • 55. Antiarrhythmics • 56. Positive inotropic drugs • 57. Antiplatelet agents, antianaemics • 58. Fibrinolytics, antifibrinolytics, haemostatics • 59. Anticoagulants • 60. Drugs causing addiction and substances used for treatment of addiction • 61. General principles of drug poisoning, specific antidotes and their mechanisms of action • 62. Drugs used in erectile dysfunction and BHP • 63. Antiglaucomatics and cycloplegics

Essential drugs:

5-fluorouracil • acetylcysteine • acetalsalicylic acid • aciclovir • allopurinol • amiodarone • amlodipine • amphotericin B • aprepitant • atorvastatin • atropine • betahistine • buprenorphine • carbamazepine • caspofungin • cefuroxime • cetirizine • ciprofloxacin • cisplatin • clarithromycin • clopidogrel • co-amoxicillin • codeine • cotrimoxazole • cyclophosphamide • ciclosporin • cyproterone • dabigatran • desflurane • diazepam • digoxin • dobutamine • doxazosin • doxorubicin • doxycycline • empagliflozin • enoxaparin • escitalopram • ethinylestradiol • ezetimibe • famotidine • fenpiverinium/pitofenone •fentanyl • finasteride • fluconazole • furosemide • gabapentin • gentamicin • haloperidol • hexoprenaline • ibuprofen • imatinib • indapamide • indometacin • insulin analogues • interferons • ipratropium-bromide • isosorbide dinitrate • ketamine • lactulose • levodopa/carbidopa • levonorgestrel • lidocaine • linagliptin • lithium • loperamide • meropenem • metamizole • metformin • methadone • methotrexate • methyldopa • methylphenidate • metoclopramide • metoprolol • mirtazapine • morphine • naloxone • nimesulide • nivolumab • noradrenaline • olanzapine • ondansetron • oxymetazoline • oxytocin • paclitaxel • pantoprazole • paracetamol • perindopril • phenoxymethylpenicillin • pilocarpine • piperacillin/tazobactam • prednisone • propofol • rivaroxaban • rivastigmine • salbutamol • sildenafil • solifenacin • spironolactone • sumatriptan • suxamethonium • tamoxifen • telmisartan • tenofovir • terbinafine • tramadol • trastuzumab • valproic acid • vancomycin • verapamil • warfarin • zolpidem

Další komentáře

Předmět je vyučován každoročně.

Nachází se v prerekvizitách jiných předmětů

Předmět je zařazen také v obdobích podzim 2017, podzim 2018, podzim 2019, podzim 2020, podzim 2021, podzim 2022, podzim 2023.

Statistika zápisu (nejnovější)
Permalink: https://is.muni.cz/predmet/med/podzim2024/aVLFA0721p

LF:aVLFA0721p Farmakologie I - přednáška - Informace o předmětu

aVLFA0721p Farmakologie I - přednáška

Další aplikace